1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 CANCER/TUMOR PROFILING CANCER TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET CANCER TYPE ANALYSIS, 2015-2019
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 BREAST CANCER
5.6 LUNG CANCER
5.7 COLORECTAL CANCER
5.8 PROSTATE CANCER
5.9 MELANOMA CANCER
5.10 OTHER CANCER
6 CANCER/TUMOR PROFILING MARKET BIOMARKER CANCER TYPE ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET BIOMARKER CANCER TYPE ANALYSIS, 2015-2019
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 BIOMARKER TYPE
6.6 GENOMIC BIOMARKER
6.7 PROTEIN BIOMARKER
7 CANCER/TUMOR PROFILING MARKET TECHNOLOGY ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET TECHNOLOGY ANALYSIS, 2015-2019
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 MICROARRAY
7.6 NEXT-GENERATION SEQUENCING (NGS)
7.7 QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR)
7.8 IMMUNOHISTOCHEMISTRY (IHC)
7.9 IN SITU HYBRIDIZATION (ISH)
7.9.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
7.9.2 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)
7.10 OTHERS
8 CANCER/TUMOR PROFILING MARKET TECHNIQUE ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET TECHNIQUE ANALYSIS, 2015-2019
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 GENOMICS
8.6 PROTEOMICS
8.7 EPIGENETICS
8.8 METABOLOMICS
9 CANCER/TUMOR PROFILING MARKET APPLICATION ANALYSIS
9.1 INTRODUCTION
9.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019
9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
9.4 Y-O-Y GROWTH TREND ANALYSIS
9.5 CLINICAL APPLICATION
9.6 RESEARCH APPLICATION
10 GLOBAL CANCER/TUMOR PROFILING REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.2.3 Y-O-Y GROWTH TREND ANALYSIS
10.2.3.1 U.S.
10.2.3.2 Canada
10.2.3.3 Mexico
10.3 ASIA-PACIFIC
10.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.3.2 Y-O-Y GROWTH TREND ANALYSIS
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 Korea
10.3.2.4 India
10.3.2.5 Southeast Asia
10.4 MIDDLE EAST AND AFRICA
10.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.4.3 Y-O-Y GROWTH TREND ANALYSIS
10.4.3.1 Saudi Arabia
10.4.3.2 UAE
10.4.3.3 Egypt
10.4.3.4 Nigeria
10.4.3.5 South Africa
10.5 EUROPE
10.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.5.3 Y-O-Y GROWTH TREND ANALYSIS
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 UK
10.5.3.4 Russia
10.5.3.5 Italy
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.6.3 Y-O-Y GROWTH TREND ANALYSIS
10.6.3.1 Brazil
10.6.3.2 Argentina
10.6.3.3 Columbia
11 MARKET PLAYERS
11.1 ILLUMINA, INC.
11.1.1 BUSINESS OVERVIEW:
11.1.2 PRODUCT PORTFOLIO
11.1.3 RECENT DEVELOPMENTS
11.1.4 SWOT ANALYSIS:
11.2 QIAGEN N.V.
11.3 NEOGENOMICS LABORATORIES, INC.
11.4 HTG MOLECULAR DIAGNOSTICS, INC.
11.5 GENOMIC HEALTH INC.
11.6 CARIS LIFE SCIENCES
11.7 HELOMICS CORPORATION
11.8 NANOSTRING TECHNOLOGIES, INC.
11.9 RIBOMED BIOTECHNOLOGIES, INC.
11.10 OXFORD GENE TECHNOLOGY
11.11 ROCHE MOLECULAR SYSTEMS INC
11.12 ABOTT MOLECULAR
11.13 HOLOGIC GEN-PROBE
11.14 BD BIOSCIENCES
11.15 SIEMENS HEALTHINEERS
11.16 PERSONAL GENOME DIAGNOSTICS, INC
11.17 PERTHERA, INC.
11.18 FOUNDATION MEDICINE, INC. V.
11.19 STRAND
11.20 APOCELL
11.21 CONTEXTUAL GENOMICS
11.22 AGENDIA
11.23 GENSCRIPT
12 ABOUT US

TABLE 1 CANCER/TUMOR PROFILING REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 2 GLOBAL CANCER/TUMOR PROFILING MARKET, 2020–2030, (USD MILLION)
TABLE 3 CANCER/TUMOR PROFILING CURRENT AND FUTURE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 4 GLOBAL CANCER/TUMOR PROFILING HISTORICAL MARKET CANCER TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 5 CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 6 GLOBAL CANCER/TUMOR PROFILING HISTORICAL MARKET BIOMARKER CANCER TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 7 CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 8 GLOBAL CANCER/TUMOR PROFILING HISTORICAL MARKET TECHNOLOGY ANALYSIS, 2015-2019, (USD MILLION)
TABLE 9 CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 10 GLOBAL CANCER/TUMOR PROFILING HISTORICAL MARKET TECHNIQUE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 11 CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 12 GLOBAL CANCER/TUMOR PROFILING HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 13 CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 14 NORTH AMERICA CANCER/TUMOR PROFILING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 15 NORTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 16 NORTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 17 NORTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 18 NORTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 19 NORTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 20 U.S. CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2015–2020
TABLE 21 U.S. CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 22 U.S. CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 23 CANADA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 24 CANADA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 25 MEXICO CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 26 MEXICO CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 27 APAC CANCER/TUMOR PROFILING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 28 ASIA-PACIFIC CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 33 CHINA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 34 CHINA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 35 JAPAN CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 36 JAPAN CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 37 KOREA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 38 KOREA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 39 INDIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 40 INDIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 41 SOUTHEAST ASIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 42 SOUTHEAST ASIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 49 SAUDI ARABIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 50 SAUDI ARABIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 51 UAE CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 52 UAE CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 53 EGYPT CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 54 EGYPT CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 55 NIGERIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 56 NIGERIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 57 SOUTH AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 58 SOUTH AFRICA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 59 EUROPE CANCER/TUMOR PROFILING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 60 EUROPE CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 61 EUROPE CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 62 EUROPE CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 63 EUROPE CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 64 EUROPE CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 65 GERMANY CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 66 GERMANY CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 67 FRANCE CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 68 FRANCE CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 69 UK CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 70 UK CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 71 RUSSIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 72 RUSSIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 73 ITALY CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 74 ITALY CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 75 SOUTH AMERICA CANCER/TUMOR PROFILING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 76 SOUTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 77 SOUTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE BIOMARKER CANCER TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 78 SOUTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 79 TABLE 82 SOUTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE TECHNIQUE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 80 SOUTH AMERICA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 81 BRAZIL CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 82 BRAZIL CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 83 ARGENTINA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 84 ARGENTINA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 85 COLUMBIA CANCER/TUMOR PROFILING CURRENT AND FUTURE CANCER TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 86 COLUMBIA CANCER/TUMOR PROFILING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)